Marinus Pharmaceuticals, Inc., a pioneering force in the development of innovative therapeutics for seizure disorders, has announced the successful closure of a significant funding round, securing $151 million to further its mission of transforming the lives of those affected by epilepsy and other seizure-related conditions. This substantial financial injection will enable Marinus to advance its ongoing clinical trials and accelerate the development of its promising pipeline of therapies. As a leader in the realm of neurological treatment, Marinus is committed to addressing unmet medical needs, particularly for patients who struggle with refractory seizures that are resistant to conventional treatments. The funds will be allocated towards the advancement of their lead candidate, which is gaining momentum in clinical testing, as well as to bolster research initiatives and enhance the company's operational capabilities. With this new capital, Marinus aims to not only improve patient outcomes but also to expand access to its groundbreaking solutions in the epilepsy treatment landscape. The support from investors reflects a growing confidence in Marinus Pharmaceuticals and its vision for a world where seizure disorders are managed effectively, enabling patients to lead fuller, more independent lives. As the company moves forward, it remains steadfast in its commitment to innovation and excellence in the field of neurology, striving to bring hope and therapeutic breakthroughs to millions of individuals impacted by seizure disorders globally.
Marinus Pharmaceuticals Secures $151 Million in Funding for Seizure Disorder Therapeutics Development
Recently funded 路 $151.0MPharmaceutical Manufacturing
Get the full Marinus Pharma company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
